Barcelona, Spain (PRWEB) October 30, 2007
Bioiberica highlights two 2007 research studies recommending the use of chondroitin sulfate (CS) as first treatment option for osteoarthritis (OA).
One of the studies, published in 2007 by Elsevier Ltd., focuses on OARSI (Osteoarthritis Research Society International) recommendations for the management of hip and knee OA. The researchers, led by W. Zhang, Ph.D., conducted a critical appraisal of published guidelines for treating OA as a prelude to creating a new, updated, evidence-based consensus of recommendations. Overall, they identified 51 different treatment modalities, 20 of which were universally recommended. One figure in the study, purporting to show pain relief with pharmacological therapies, places glucosamine and chondroitin sulfate within the top three options, along with intra-articular corticosteroids.
Another recent study published in Rheumatology in 2007 was carried out by M. Pocheret et al. in collaboration with the UK Primary Care Rheumatology Society with the aim of developing an evidence-based model of care for the treatment of knee pain in older adults. This study concludes that CS should be offered to all knee pain sufferers as a first step intervention.
These systematic reviews and recommendations on OA performed by international independent groups such as OARSI and the UK Primary Care Rheumatology Society are in line with the previous recommendations of the European League Against Rheumatism (EULAR), which were recently published including and recommending treatment with CS. They all conclude that CS has the highest level of evidence and strength of recommendation due to its efficacy on pain and disability, together with its high level of safety.
CS is included in a group of modalities called Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA). Classified as a dietary supplement in the United States, CS is regarded as a drug in Europe and many parts of the world and as such has been the subject of a growing body of clinical evidence to prove its efficacy and safety.
Current evidence indicates that oral administration of CS produces a slow but gradual decrease in clinical symptoms of OA, inducing pain reduction and improvement of functional capacity compared to nonsteroidal anti-inflammatory drugs (NSAID's) and placebo. This effect persists for at least 3 months after cessation of treatment.
As regards to safety, all the clinical trials, meta-analyses and pharmacosurveillance conducted in Europe, where CS is regulated as a drug, conclude that it is safe. For over 10 years there has been no serious adverse events or pharmacological interactions with other drugs. This is particularly important for older patients, who make up the largest overall group of OA patients, and may suffer concomitantly of high blood pressure, diabetes, etc., in which the use of analgesics and NSAIDs is not free from risks.
Considering the positive effect of CS on disease progression, its symptomatic efficacy and its high safety profile and additional advantage on reducing analgesic and NSAID consumption, CS offers a safe and effective alternative in patients with symptomatic OA.
Among CS ingredients available in the marketplace, CSb™ Bio-Active, developed by the Spanish company, Bioiberica, has been used in more published studies than any other brand. It was featured in the groundbreaking GAIT (Glucosamine/Chondroitin Arthritis Intervention) study and can be found in exclusivity in Cosamin DS in the USA. Since the early 1980s, CSb™ Bio-Active has helped more than 15 million people worldwide relieve the symptoms of OA.
Bioiberica has become a recognized leader in joint health. Established in 1975, the company has pioneered advancements in pharmaceuticals and dietary supplements that have led to the development of a global business in over 40 countries around the world. Dedicated to research, Bioiberica has established itself as on of the most prestigious names in the industry for top-quality raw materials that are backed by science.
For more information on the science supporting the use of CS, visit http://www.csbioactive.com .
To arrange an interview with a company spokesperson or a member of the medical advisory panel, please contact Tamara York at ADinfinitum, 212.693.2150, Ext 314, or email at tamara(at)adinfinitumny.com.
# # #